LongBio Pharma (Suzhou) Co., Ltd. (HKG:1779)

Market Cap	4.65B
Revenue (ttm)	n/a
Net Income	-249.58M
EPS	-4.04
Shares Out	76.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,700
Open	57.30
Previous Close	57.05
Day's Range	57.30 - 61.35
52-Week Range	43.20 - 165.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About LongBio Pharma (Suzhou)

LongBio Pharma (Suzhou) Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, manufacture, and commercialization of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. It develops LP-003, an anti-immunoglobulin antibody with novel sequencing; LP-005, bi-functional antibody fusion protein for autoimmune diseases; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 94
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1779

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error